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Mefenamic acid (MFA) is a hydrophobic drug with low dissolution rate. This study aimed to develop 
stable and reproducible aqueous formulations of MFA using liposomes as drug carriers. The drug 
entrapment, particles size and drug release profiles, and stability and reproducibility of the liposomes 
were determined. In addition, the maximum tolerated dose (MTD) was determined in rats via the oral 
and intraperitoneal routes of administration. Also, the anti-inflammatory efficacy of these liposomes was 
evaluated using carrageenan-induced paw edema model in rats. MFA-DDC based liposomes demonstrated 
a drug entrapment efficacy of 93.6%, particles size of 170.9 nm, and polydispersity index of 0.24 which 
were not statistically affected when stored in room and refrigerated temperatures for at least 4 weeks. 
The MTD of the intraperitoneally administrated MFA-loaded liposomes was 20 mg MFA/kg, whereas 
for those of oral administrations, it was up to 80 mg MFA/kg. Intraperitoneal dose (80 mg MFA/kg) of 
MFA-DDC liposomes induced extrapyramidal symptoms associated with significant elevation in serum 
potassium and muscle enzymes. Moreover, significant inhibition of paw edema was demonstrated by the 
oral and intraperitoneal routes. These findings suggest that MFA-DDC based liposomes are an effective 
formulation of MFA and recommend the use of bioequivalence assessments with commercial formulations.
Keywords: Mefenamic acid. Liposomes-characterization. Sodium diethyldithiocarbamate. 
Extrapyramidal symptoms. Carrageenan.
INTRODUCTION
Mefenamic acid (MFA) is a member of NSAIDs 
which poses anti-inflammatory, anti-nociceptive, and 
antipyretic properties (Cimolai, 2013). According to the 
biopharmaceutical classification system, this drug belongs 
to class II drugs which are characterized by poor water 
solubility and low dissolution rate (Abdul Mudalip et al., 
2013). The insufficient solubility of MFA usually results 
in poor bioavailability and gives suboptimaltherapeutic 
responses. Considerable efforts have been given to 
enhance MFA water solubility as a key element in 
improving its bioavailability with little progress (Abdul 
Mudalip et al., 2013; Imai et al., 1991). 
L iposomes  a r e  d rug  nanoca r r i e r s  wh ich 
basically consist of phospholipids bilayer (s) and 
pose amphiphilic nature that allows entrapping both 
hydrophilic and hydrophobic drugs and exhibits multiple 
biopharmaceutical functions (Bozzuto, Molinari, 2015). 
Liposomes can enhance drugs solubility, improve 
bioavailability, and protect the entrapped drug from 
enzymatic degradation (Bozzuto, Molinari, 2015; Kim, 
Kim Lee, 2013). Moreover, liposomes provide sustained 
drug release, enhance drug cellular uptake, allow specific 
tissue targeting, and delay drug clearance (Fricker et 
al., 2010). However, the in vivo performance of the 
liposomes depends extensively on their physicochemical 
properties including their chemical constituents, drug 
entrapment capacity, size profiles, liposome surface 
charge, pH sensitivity, and drug release properties (Gatoo 
et al., 2014). Determining the in vitro characteristics of 
liposomes constitutes a basic requirement for prediction 
the in vivo performance of the liposomes and selection 
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of the most suited route of administration. Methods used 
in liposomes preparation differ in their ability to scale up 
liposomes production (Wagner, Vorauer-Uhl, 2010). Also, 
these methods yield liposomes of different encapsulation 
efficacy, particles size, and shelf lives stability.
Sodium diethyl dithiocarbamate (DDC), the main 
metabolite of disulfiram, has been used in a combination 
therapy with NSAIDs to improve their therapeutic efficacy 
and reduce their toxicity due to the wide spectrum of 
pharmacodynamic activities and unique properties 
(Lai, Wang, 2002). It is utilized in metals chelating, free 
radicals scavenging, and modification of liver enzyme 
metabolism. These together, enable DDC to restore the 
immune functions, regulate the inflammatory responses, 
exert anti-inflammatory properties, work as an antidote 
for drug poisonings, inhibit the progression of AIDS and 
fungal infections, and kill various types of neoplastic cells 
(Martinez-Martinez et al., 1997).
Mefenamic acid-sodium diethyldithiocarbamate 
based liposomes (MFA-DDC based liposomes) were 
recently prepared in our laboratory. The present work 
aimed to evaluate the efficacy and toxicity of these 
liposomes via different routes of administration.
MATERIAL AND METHODS
Reagents
All chemicals and reagents used in this study were 
of analytical grade and used without further purification. 
Pure MFA powder and sodium diethyldithiocarbamate 
(DDC) were purchased from Sigma-Aldrich (The United 
States), dimethyl sulfoxide (DMSO) 99.5% from Sigma 
Life Science (The United States), and Univar (France), 
Pro-Lipo Duo from Lucas Meyer France. 
Preparation of MFA-DDC based liposomes
Mefenamic acid-DDC based liposomes were 
prepared from a commercial phospholipids mixture 
(Pro-lipo duo®) according to the manufacturer’s (Lucas 
Mayer, France) instructions with some modifications. 
Briefly, a drug solution was prepared by dissolving an 
equivalent amount of MFA and DDC (100 mg each) in 
DMSO. The drug solution was then added to Pro-Lipo 
Duo and mixed on a magnetic stirrer at moderate speed 
(100 RPM) for 1 hour. Next, the mixture was gradually 
hydrated with Tween 20 aqueous solution (0.004% w/w) 
and continuously mixed for a predetermined period 1, 
5 or 10 hour(s). Following hydration, the concentrated 
liposomal dispersion was diluted with ultra-purified water 
and mixed for another 30 minutes. In all formulations, the 
ratio of MFA: DDC: DMSO: Pro-Lipo Duo: Hydration 
media: ultra-purified water (dilution) was 1:1: 4: 20: 36: 
100 w/w, respectively.
For comparison purposes, MFA free-liposomes 
and DDC free-liposomes were prepared using the same 
procedure without MFA and/or DDC.
Preparation of sonicated MFA-DDC based 
liposomes
Freshly prepared samples (n=6) of MFA-DDC 
based liposomes were sonicated in 300 W and 35 °C bath 
sonicator (Digital Pro Heated Ultrasonic Cleaner, Huiyuan 
Int’ Commerce & Exhibition Co., China) for 60 minutes 
(Woodbury et al., 2006).
Preparation of lyophilized MFA-DDC based 
liposomes
Freshly prepared MFA-DDC based liposomes (n=6), 
with or without inclusion of sucrose (4 g/g Pro-Lipo Duo) 
during hydration procedure, were kept overnight in an 
ultra-low freezer (-80 °C) (Sanyo Electric CO. Lt, Japan) 
and lyophilized using freeze dryer (LTE Scientific Ltd, 
Great Britain). The drying powders obtained were then 
reconstituted to the original volume using ultra-purified 
water (Kannan et al., 2015). 
In-vitro characterization of MFA-DDC based 
liposomes
Validation assay
Detection and quantification of MFA in the 
prepared liposomal samples were conducted using a new 
spectrophotometric method. Validation parameters included 
selectivity, linearity, accuracy and precision, limit of 
detection (LOD), and limit of quantification (LOQ) as per 
International Council for Harmonisation (ICH) guideline.
Selectivity: The optical density of drug solution 
(25 µg/mL) and serial dilutions of blank liposomal samples 
were measured over UV range (260-400 nm). DMSO was 
used as a blank while the ultra-purified water was used as 
a standard for measurements. The wavelength at which 
the drug showed significant absorption with no significant 
influence of the liposome components was selected for 
measurement of MFA absorptions. 
Linearity: Linear regression curve analyses were 
performed by Microsoft Office Exel 2010 software 
In vitro characterization and in vivo performance of mefenamic acid-sodium diethyldithiocarbamate based liposomes
Braz. J. Pharm. Sci. 2019;55:e17870 Page 3 / 13
(Microsoft, US). The calibration curve was constructed 
by plotting standard drug concentrations (80, 40, 20, 10, 
and 5 µg/mL) of serial dilution on X-axis and the obtained 
drug absorptions on Y -axis.
Accuracy and precision (Intraday and Interday 
Validations): Intraday validations were performed by 
measuring the absorbance of six sets of six selected 
concentrations (75, 65, 55, 45, 35, and 25 µg/mL) of 
MFA solutions in a single day. On the other hand, interday 
validations were performed by measuring the absorbance 
of a single set of six selected concentrations (75, 65, 55, 45, 
35, and 25 µg/mL) using six calibration curves constructed 
at different days. Percent coefficient of variation (% CV) 
and percent error of the average means were calculated 
to evaluate the precision and accuracy of the method 
according to the following formulas:
% error = (Mean of experimental values – True value)/
True value) × 100
% CV= (Standard deviation / Mean) × 100
Limit of detection and limit of quantitation: Limit 
of Detection (LD) and Limit of Quantitation (LQ) were 
determined by using the following formulas: LD= 3.3 σ/S, 
LQ= 10 σ/S respectively, where σ = the standard deviation 
of the response (20 replicates of the blank) and S = the 
slope of the calibration curve.
Drug entrapment analysis
The amount of drug entrapped in MFA-DDC based 
liposomes was determined according to the procedure 
described by Goh et al. (2014) _ENREF_9and Chiong et 
al. (2011). All drug amounts were obtained by using the 
above mentioned spectrophotometric method. The amount 
of undissolved drug was determined by centrifuging the 
samples at 12800 G and dissolving the sediment with 
sufficient amount of DMSO. The dissolved drug was 
determined by centrifuging the samples at 300,000 G and 
20 °C for 90 minutes and diluting the supernatant with 
sufficient amount of DMSO. The encapsulation efficacy 
was calculated according to following formula: EE (%) = 
(Total drug - Free drug)/(Total drug)×100, where free drug 
equals the sum of the undissolved drug and the dissolved 
drug.
Particle size analysis
The average particle size (ZAve), polydispersity 
index (PDI), and zeta potential of the prepared liposomal 
samples were all determined by dynamic light scattering 
technique using Zetasizer Nano S (Malvern Instruments, 
Malvern, UK) (Onget al., 2016). Light scattering was 
monitored at 25 °C, with measurement position of 1.25 
mm. In addition to MFA-DDC based liposomes, MFA 
free-liposomes and MFA-DDC free liposomes were 
subjected to analysis for comparison. For all formulations, 
the measurements were conducted three times on the three 
individual batches of freshly prepared liposomal samples 
(n= 9).
Size reduction analysis
The effects of sonication and freeze-drying on the 
drug entrapment and size profiles of MFA-DDC based 
liposomes were evaluated. Upon comparison with non-
treated MFA-DDC based liposomes, the drug entrapment 
and particles size parameters of sonicated and lyophilized 
liposomes were determined according to procedures 
described above. For all formulations, the measurements 
were conducted three times on the three individual batches 
of freshly prepared liposomal samples (n= 9).
Drug release at different pH media
The amount of drug released (free MFA) was 
determined according to a previously described procedure 
using the sample and separate method (D’Souza, 2014). 
An aliquot of freshly prepared samples (n=3) of MFA-
DDC liposomes was added into beakers and mixed 
continuously with a release media (pH 1.2, pH 5.4, or pH 
7.4 for 7 hours) at 100 RPM and 37 °C using a magnetic 
stirrer. At each hour during experimentation, an aliquot 
of the mixture was withdrawn and replaced with fresh 
medium. The aliquot was then centrifuged, and the content 
of free drug was determined by a spectrophotometer as 
described above. 
Storage study
The effect of different storage condition on the 
physical stability of MFA-DDC based liposomes was 
evaluated with respect to their drug entrapment and size 
profiles. Three batches of liposomal samples were freshly 
prepared, and each was separated and stored at ambient 
room temperature (25±3 °C) and refrigerated temperature 
(2-8 °C). Samples for analyses were collected immediately 
and at two and four weeks after preparation (Chiong et al., 
2011; Goh et al., 2014).
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Reproducibility
The coefficient variation percentage (% CV) of six 
different batches of the liposomal samples was calculated 
to assess the reproducibility of MFA-DDC liposomes 
with respect to their drug entrapment and particle size 
parameters (Chiong et al., 2011; Goh et al., 2014).
Experimental animals 
 Forty-eight female Sprague-Dawley rats with 
body weight of 180-220 g were used in the present 
study. All rats were housed at 12 h light of the day and 
(24 ±1°C) room temperature at the Faculty of Medicine 
and Health Sciences, Universiti Putra Malaysia (UPM). 
All animals were housed in clean wire-bottomed plastic 
cages with well-ventilated laboratory conditions and 
had free access to standard food pellets and drinking tap 
water. All experiments were carried out according to the 
protocol approved by the ethical committee of UPM and 
in accordance with the UPM Institutional Animal Care and 
Use Committee.
Maximum tolerated doses selection 
Eight groups (6 rats each) received a single dose of 
either oral or intraperitoneal liposomal MFA (0, 20, 40, 
and 80 mg/kg) at equivalent doses. All treated rats were 
observed during the post dosage periods for any signs of 
toxicity. The dose at which rats showed normal activity and 
behavior was selected as the MTDs in the present study.
Biochemical analysis
At six hours after liposomal MFA exposure, 
blood samples were collected and centrifuged at 3000 
G for 15 minutes for serum separation. Serum samples 
were immediately assayed to determine aspartate 
aminotransferase (AST), creatine kinase (CK), lactate 
dehydrogenase (LDH), and serum electrolytes such as 
sodium, potassium, and chloride. 
Carrageenan induced acute paw edema test
Six groups of rats (6 each) received a single oral dose 
(0, 20, 40, and 80 mg/kg) and intraperitoneal dose (0 and 
20 mg/kg) of MFA-DDC based liposomes. The rats were 
then subjected to carrageenan induced with acute paw 
edema test according to the experimental protocol of Neha 
Mohan et al. (2013).The overnight fasting rats received 
the treatments 30 minutes before they were induced with 
paw inflammation by injecting 100 μL of carrageenan (1%, 
W/V) into the left paw of each rat. The hind paw volume 
of each rat was then measured using a plethysmometer 
(Basile Ugo, Italy) at 0, 1, 2, 3, 4, 5, and 6 hours after 
carrageenan injection. The percentage of edema inhibition 
was calculated according to the following formula:
where V0 is initial paw volume, and Vt is the paw volume 
at a specific time point. 
Statistical analysis
All results were presented as mean ± SEM. The 
comparative analysis was conducted using Student’s t-test 
for comparisons between two groups and one-way analysis 
of variance (ANOVA) for multiple comparisons (IBM 
SPSS Statistics 20). The P-value < 0.05 was considered 
statistically significant. 
RESULTS AND DISCUSSION
Spectrophotometric method validation 
Drug analysis must be conducted using valid 
methods to show a degree of selectivity, sensitivity 
accuracy, and precision that matches the analytical 
requirements (Kunasekaran, Krishnamoorthy, 2014; 
Siddiqui, Alothman, Rahman, 2013; Wagner, Vorauer-Uhl, 
2010). In the present study, a simple, rapid, effective, and 
cost-saving method was developed for MFA detection and 
quantification in liposomal preparations.
Spectrum scanning analysis showed that MFA 
has UV absorption at the wavelength range of 240-360 
nm (Figure 1). However, the comparative findings of 
ultra-pure water standard spectra with those of MFA free-
liposomal samples showed satisfied selectivity at 360 
nm where liposome components showed no significant 
interference with MFA absorption. Data obtained from 
MFA standard calibration curve showed a high correlation 
between test drug concentrations and corresponding 
absorbance values with a correlation coefficient of 0.999 
and linearity range of 5-80 µg/mL (Figure 2). In addition, 
all intraday and interday method validations as per ICH 
guideline showed acceptable precision and accuracy 
values with the coefficient of variation and percentage 
error less than 5% with different drug concentrations. 
In addition, the limit of detection (LOD) and limit of 
quantification (LOQ) were found to be 1.19 and 3.62 μg/
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mL, respectively. Together, these findings suggest that 
the described spectrophotometric method is valid for 
MFA analysis in the liposomal preparations. In addition, 
this method is rapid and cost-effective which may be 
suitable for analysis of a large number of samples. Unlike 
previously described spectrophotometric methods, the 
use of DMSO (as drug solvent) in the present method 
is effective to dissolve a high amount of MFA which 
increases the suitability for a detection of a wide range of 
drug concentrations (Dinç, Yücesoy, Onur, 2002; Othman, 
Awadis, 2009). Furthermore, the method introduced by 
the present study does not require additional analytical 
reagents in contrast to some previously described methods 
(Alarfaj, Altamimi, Almarshady, 2009). 
In vitro characterization of MFA-DDC based 
liposomes
Drug entrapment and particle size profiles
Figures (3-6) show the influence of liposomes 
chemical components (with or without DDC) and 
prolongation of hydration time on drug entrapment and size 
parameters. As demonstrated in Figure 3, the encapsulation 
efficacy of MFA-DDC based liposomes was approximately 
nine-fold greater than that of MFA-DDC free liposomes 
when different hydration times were employed. The results 
indicate that MFA-DDC liposomes are able to entrap 
47.04 mg of MFA/g Pro-Lipo Duo, whereas MFA-DDC 
free liposomes were not able to entrap more than 7.7 mg 
of MFA/g Pro-Lipo Duo. No significant change in drug 
entrapment efficacy of all prepared liposomes was observed 
by the Tukey’s test when prolongation of hydration time (up 
to 10 hours) was employed.
Also, the results showed that MFA-DDC based 
liposomes demonstrated significantly (p< 0.05) smaller 
particles size than those of MFA-DDC free liposomes 
when different hydration times were employed (Figure 
4). No significant change in the size profiles of all 
prepared liposomes was observed by the Tukey’s test 
when prolongation of hydration time (up to 10 hours) was 
employed. Together, these findings may indicate that the 
physical properties of MFA-loaded liposomes prepared in 
the present study are largely dependent on the chemical 
additives to these liposomes rather than the prolongation 
of hydration time. The improvement in the encapsulation 
efficacy and particles size reduction by DDC involvement 
may suggest structural alterations on the phospholipids of 
Pro Lipo Duo. Studies indicated the ability of DDC to form 
bridging ligands and pose strong binding properties with 
various therapeutic agents (Han et al., 2013; Lai, Wang, 
2002; Wehbe et al., 2016).
The polydispersity index (PDI) of all liposomes in 
the present study including MFA-DDC based liposomes 
ranged from 0.2-0.35 (Figure 5). The PDI is a measurement 
that reflects the uniformity of particle sizes of colloidal 
dispersions; the homogenous vesicles give values ranging 
from 0-0.5 while those of the heterogeneous ones give 
values ranging from 0.5-1.0 (Wen, Farid, Kassem, 2014; 
Zhang, Fan, Smith, 2009). The findings of the current work 
indicate narrow particle size distribution of all prepared 
liposomes. 
Zeta potential is a value that reflects the strength of 
electrostatic repulsion between similarly charged particles 
and indicates colloids stability (MuÈller, MaÈder, Gohla, 
2000; Wen, Farid, Kassem, 2014). Vesicles that give ZP 
values more than ±30 Mv pose strong repulsive forces and 
have less potential to develop aggregation or flocculation 
(Frestaet al.,1993; Wen, Farid, Kassem, 2014). As shown 
in Figure 6, ZP of all liposomal formulations including 
MFA-DDC based liposomes ranged from -45.80 to -77.90. 
These results suggest that all liposomal preparations used 
in the present work have colloidal stability resulted from 
FIGURE 1 - UV spectrum of MFA (25 μg/mL) dissolved in 
DMSO at a wavelength range of 200-360 nm.
FIGURE 2 - Mefenamic acid calibration curve constructed via 
standard solution with five concentrations in the range from 
5-80 μg/mL.
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strong electrostatic repulsion between liposomes (Dinç, 
Yücesoy, Onur, 2002; Samad, Sultana, Aqil, 2007).
Effect of sonication and lyophilization on drug 
entrapment and size profiles of liposomes
Small liposomes pose several advantages over 
big liposomes with respect to their longer circulating 
half-lives and better tissue penetration. Previous studies 
indicated that particle size of liposomes could impact 
the interaction of the entrapped drug with cells, its 
circulation half-life, and bioavailability (Chen, Langer, 
1998; Chen et al., 2011; Elorza et al., 1993).
Several methods are employed to reduce particle 
size of liposomes including sonication and freeze-
drying methods (Lee, Lee & Choi, 2007). In the present 
study, MFA-DDC based liposomes were subjected to 
lyophilization (with or without sucrose) and sonication to 
discover their effect on the liposomes size and their drug 
entrapment profile.
As presented in Table I, sonication slightly increased 
the average particle size (from 173.16 to 184.29 nm). 
On the other hand, lyophilization with sucrose reduced 
the particle size from 173.16 nm to 144.12 nm, while 
lyophilization without sucrose increased the particle size 
FIGURE 3 - Entrapment efficiency (%) when different liposomal 
components and duration of hydration were employed. (*) 
Indicates statistically significant difference between the 
formulations by the Student’s t-test.
FIGURE 4 - Particle size (nm) when different liposomal 
components and hydration times were employed. (a) Indicates 
significant difference between MFA-loaded liposomes and their 
corresponding MFA free-liposomes by the Student’s t-test. 
(b) Indicates significant difference between MFA-DDC free 
liposomes and MFA-DDC based liposomes by the Student’s 
t-test. (c) Indicates significant difference between MFA free-
DDC free liposomes and MFA free-DDC based liposomes by 
the Student’s t-test.
FIGURE 5 - Polydispersity index of the particles size when 
different liposomal components and hydration times were 
employed.
FIGURE 6 - Zeta potential (mv) when different liposomal 
components and duration of hydration employed.
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up to 377.16 nm. Moreover, the PDI value was not affected 
by sucrose-lyophilization, but it increased in lyophilization 
without sucrose and sonication. All these suggests that 
only lyophilization with sucrose was effective to reduce 
the particles size in narrow size distribution, indicating 
that sucrose provides a cryoprotective effect that partially 
prevents liposomes fusion during the lyophilization 
process. Nevertheless, both sonication and lyophilization 
(with or without sucrose) caused significant (P<0.05) 
reduction in drug entrapment efficacy and capacity, 
suggesting that these techniques will not be suitable to 
produce small MFA-DDC liposomes.
Effect of pH on drug release properties
The pH differences between various tissue and 
cellular environments of the human body can be a limiting 
factor on drug release profile from the liposomes (Chu, 
Szoka, 1994). For example, pH-sensitive liposomes 
provide a controlled drug release in cancer and inflamed 
tissues where the intracellular pH ranges from 4-6 (Mo, 
Gu, 2016; Steen, Steen, Reeh, 1995). In the current study, 
MFA release from the liposomes was evaluated in various 
pH (1.2, 5.4, and 7.4) media over 7 hours. MFA-DDC 
based liposomes provided a pH-dependent gradient drug 
release as drug release significantly (p< 0.05) increased 
by decreasing the pH of the media (Figure 7). The robust 
release of MFA in the strongly acidic medium (pH 1.2) 
may suggest that these liposomes are relatively not stable 
in the gastric fluid and not effective by the oral route of 
administration (Thamphiwatana et al., 2013). On the other 
hand, these liposomes caused small burst and sustained 
drug release in pH 5.4 medium that may suggest the 
suitability of these liposomes in targeting inflamed tissues 
that have weak acidic environments (Steen, Steen, Reeh, 
1995). In addition, the drug release at pH 7.4 was almost 
“off” (less than 12%) which may indicate the stability 
of these liposomes in the blood that can avoid fast drug 
release, reduce the systemic side effects, and prevent drug 
uptake by the untargeted tissues (Sercombe et al., 2015). 
All these results may indicate that the developed liposomes 
may enhance MFA targeting to the inflamed tissues, 
considering the use of other routes of administration rather 
than the oral dosage in order to achieve the maximum 
therapeutic benefits by liposomes encapsulation of MFA.
Effect of storage conditions on drug entrapment 
and particle size of MFA-DDC liposomes
Storage study is important to determine the physical 
TABLE I – Drug entrapment and particle size profile before and after size reduction treatments
Formulation ID
Entrapment profile Size profile
Amount entrapped 
(mg/g Pro-Lipo)
Percent 
entrapped
Particle size 
(nm)
Poly-dispersity 
index Zeta potential
MFA-DDC based liposomes 
(without treatment)
46.72 ± 0.18 93.45 ± 0.36 173.16 ± 1.63 0.23 ± 0.003 -64.81 ± 1.12
Sonicated MFA-DDC based 
liposomes
43.74 ± 0.43* 87.47 ± 0.87* 184.29 ± 1.87 0.32 ± 0.01 -61.10 ± 2.51
 Lyophilized MFA-DDC based 
liposomes (without sucrose)
45.06 ± 0.21* 90.11 ± 0.43* 377.16 ± 8.12 0.45 ± 0.02 -73.01 ± 0.21
Lyophilized MFA-DDC based 
liposomes (with sucrose)
45.73 ± 0.07* 91.47 ± 0.15* 144.12 ± 0.75 0.24 ± 0.009 -58.43 ± 0.07
(*) Indicates statistically significant difference from MFA-DDC based liposomes (without treatment) by the Dunnett’s test
FIGURE 7 - Cumulative drug release at different pH media. 
(a) Indicates significant difference between the amount of 
drug release at pH (1.2) and pH (5.4) by the Student’s t-test. 
(b) Indicates significant difference between the amount of 
drug release at pH (1.2) and pH (7.4) by the Student’s t-test. 
(c) Indicates significant difference between the amount of drug 
release at pH (5.4) and pH (7.4) by the Student’s t-test.
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stability of liposomes stored at different storage conditions. 
Improper storage ambient temperature may increase 
phospholipid membrane fluidity that may finally result in 
rapid hydrolysis of the liposomes (Samad, Sultana, Aqil, 
2007). As seen in Table II, MFA-DDC based liposomes 
stored at both room and refrigerated temperatures exhibited 
good stability with no significant difference in drug 
entrapment and particle size profile during the four weeks of 
storage. These findings indicate that the prepared liposomes 
can withstand the duration of storage whereby the quality 
of these preparations remains satisfactory or unaffected.
Reproducibility of MFA-DDC based liposomes 
Reproducibility test is important to assess the 
precision and repeatability of the results between different 
batches (Chiong et al., 2011; Goh et al., 2014). As shown 
in Table III, the percent coefficient of variation (CV %) of 
all test parameters was not found to be more than 7.2 %. 
This finding indicates that MFA-DDC based liposomes are 
reproducible via the same formulation and methodology.
Selection of the maximum tolerated doses of 
MFA-DDC based liposomes
All control rats and all members that received oral 
doses of MFA-DDC based liposomes together with those 
received intraperitoneal doses of 20 mg/kg liposomal 
MFA exhibited no signs of toxicity with normal activities 
and behaviors. On the other hand, rats that received 
intraperitoneal doses (40 and 80 mg/kg) of the liposomal 
drug exhibited acute extrapyramidal symptoms (EPS) 
mainly dystonia, akinesia, limb tremor, and dyskinesia. 
These toxicity signs were observed at distinct consecutive 
stages in a dose-dependent manner with different onset and 
duration of the reaction as elucidated in Table IV. Based 
on these findings, the MTD of the orally administrated 
of MFA-DDC based liposomes was selected at 80 mg/
kg while for those administrated intraperitoneally was 
selected at 20 mg/kg.
The extrapyramidal system is modulated by 
dopamine and regulates skeletal muscle tone (Divac et al., 
2014). Thus, the induced EPS of MFA-DDC liposomes 
may indicate an interference with the dopaminergic 
system. One of the major characteristics of EPS induced 
by MFA-DDC liposomes is an acute dystonic reaction. 
Dystonia is a neurological condition characterized by 
sustained or repetitive muscle contractions that produce 
twisting movements and abnormal postures (Albanese, 
2007). Dystonia may be genetically inherited or resulted 
from a broad range of causes including genetic mutations, 
birth injury, stroke, brain tumors, certain infections, and 
drugs treatment. Inducing dystonia in rodents would 
be a promising tool for understanding the mechanisms 
TABLE II - Drug entrapment and size entrapment of MFA- DDC liposomes kept in different storage conditions
Storage 
temperature 
(°C)
At starting time After 2 weeks After 4 weeks
Amount 
entrapped
Percent 
entrapped
Amount 
entrapped
Percent 
entrapped
Amount 
entrapped
Percent 
entrapped
23 46.82±0.06 93.63±0.11 46.97±0.12 93.94±0.24 46.90±0.09 93.80±0.18
4 46.95±0.09 93.88±0.18 47.14±0.11 94.27±0.23 47.04±0.12 94.08±0.25
TABLE III - Reproducibility of MFA-DDC based liposomes
Entrapment profile Size profile
Amount entrapped 
(mg/g Pro-Lipo)
Percent 
entrapped
Particle size 
(nm)
Polydispersity 
index
Zeta 
potential (mv)
Batch #1 46.15 92.30 186.17 0.25 -66.60
Batch #2 46.69 93.37 175.67 0.26 -70.33
Batch #3 47.10 94.20 180.73 0.27 -75.13
Batch #4 46.99 93.99 181.13 0.26 -64.83
Batch #5 47.11 94.22 169.13 0.22 -66.07
Batch #6 46.53 93.07 152.17 0.24 -71.87
Mean ± S.E.M 46.76 ± 0.15 93.53 ± 0.31 174.17 ± 4.99 0.25 ± 0.007 -69.14 ± 10.62
CV % 0.8 0.8 7 7.2 5.8
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underlying dystonia and identifying novel therapeutics in 
the clinical treatments (Raike, Jinnah, Hess, 2005). The 
present study introduces a new model for inducing acute 
dystonia in rats by MFA-DDC based liposomes. This 
model exhibits a rapid onset of dystonic reaction and poses 
distinct consecutive phases which can be easily recognized 
and scored during the experimentation.
All rats exposed to the oral administration of MFA-
DDC based liposomes demonstrated no EPS at all doses 
level. This may indicate that the intraperitoneal dosage 
of MFA-DDC based liposomes resulted in higher drug 
bioavailability than the one resulted by the oral route of 
administration. In comparison to the environment of the 
peritoneal fluids, the gastric juice has stronger acidic pH 
which may result in rapid drug release from the liposomes 
that reduces the amount of drug reaching the blood 
circulation.
Biochemical alterations induced by MFA-DDC 
liposomes
All members of the orally administrated MFA-
DDC liposomes demonstrated no biochemical alterations 
of the tested parameters. Moreover, rats subjected to 
intraperitoneal MFA-DCC liposomes showed a significant 
elevation in a dose-dependent manner (particularly 40 and 
80 mg/kg) in AST, CK, and LDH (Table V). These enzymes 
are released into the bloodstream in case of muscle injury 
or prolonged muscle contraction (Brancaccio, Lippi, 
Maffulli, 2010; Chavez et al., 2016; Elsayed, Reilly, 
2010). This may suggest that the severity of dystonia by 
MFA-DDC based liposomes can be indirectly quantified 
by measuring serum levels of AST, CK, LDH, and K+ in 
future studies.
TABLE IV - The extrapyramidal symptoms induced by intraperitoneal administrated MFA-DDC liposomes
Dose 
(mg/kg)
Developed phases
Onset 
(Minutes)
Duration 
(Minutes)
Extrapyramidal Symptoms Affected Rats (n)
20 No neuropathic 
reaction
- - Normal motor behavior -
40
Dystonic phase 2 < 1
Sudden spasmodic attack (retrocollis, 
and oromandibular dystonia), upper limb 
tremors, fingers movement like playing 
in piano, tongue flaccid, gradual loss of 
balance, and akinesia
6
Akinesia phase 2-3 18
- Complete loss of voluntary activity 
- Laying down in sleeping position  
- Total absence of the dystonic reaction
5
Recovery phase 14-24 10-38
-Legs dragging  
- Gradual return to the standing position 
- Gradual return to the motion activity 
6
80
First dystonic 
reaction phase
2-3 < 1
Sudden spasmodic attack (retrocollis, 
and oromandibular dystonia), upper limb 
tremors, tongue flaccid, gradual loss of 
balance, and akinesia
6
Akinesia phase 3-4 8-11
Complete loss of voluntary activity with total 
absence of the dystonic reaction
6
Second dystonic 
reaction phase
8-11 53-62
Complete loss of voluntary activity, 
anterocollis, and upper limb tremors
6
Recovery phase 55-60 Up to 6X60 
Gradual recovery as follows: 
- Dystonic reaction disappearance  
- Concomitantly legs drag 
- Gradual return to the standing position 
- Muscle fatigue
6
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Anti-inflammatory efficacy 
Carrageenan is sulfated polysaccharides extracted 
from red seaweeds. This compound is widely used in 
the pharmacological studies to induce short-lasting 
paw edema in animal models to assess the anti-
inflammatory properties of various chemicals including 
NSAIDs (Fehrenbacher, Vasko, Duarte, 2012). As seen 
in Table VI, all rats subjected to MFA-DDC based 
liposomes exhibited significantly (p< 0.05) higher anti-
inflammatory effect in comparison to the control group 
at various time intervals following administration. 
Orally-treated rats demonstrated dose-dependent 
reduction of paw edema volume with rapid onset of 
action observed among members that received higher 
doses of MFA. Moreover, the intraperitoneally-treated 
rats with MFA-loaded liposomes showed significantly 
(p< 0.05) less edema volume than those treated orally. 
The intraperitoneally-treated rats exhibited an inhibition 
percentage of 94.27% of the inflammation at 6 hours 
following carrageenan injection, while those receiving 
liposomes orally demonstrated a maximum of 78%. 
These findings may suggest that the intraperitoneal 
administration of MFA-loaded liposomes exhibits better 
anti-inflammatory effect at lower drug dosage than the one 
seen by the orally administrated MFA-loaded liposome.
TABLE V - Biochemical alterations demonstrated by rats exposed to oral or intraperitoneal MFA-DDC liposomes
Treatment group
Mefenamic acid 
dosage (mg/kg)
Serum muscle enzymes Serum electrolytes
AST 
(U/L)
CK 
(U/L)
LDH 
(U/L)
Na 
(mmol/L)
K 
(mmol/L)
Cl 
(mmol/L)
Orally administrated 
MFA-DDC based 
liposomes
0 (control) 107.83 ± 5.93 288.67 ± 36.88 201.33 ± 18.83 142.83 ± 1.68 4.65 ± 0.17 105.17 ± 1.62
20 116.33 ± 6.67 281.00 ± 26.45 199.50 ± 25.16 143.00 ± 5.11 4.60 ± 0.30 108.50 ± 1.86
40 109.50 ± 6.83 262.83 ± 19.39 232.33 ± 14.65 143.67 ± 3.01 4.48 ± 0.09 107.17 ± 3.05
80 125.17 ± 8.38 280.00 ± 33.27 252.67 ± 23.48 144.83 ± 4.38 4.70 ± 0.29 109.08 ± 3.00
Intraperitoneally 
administrated  
MFA-DDC based 
liposomes
0 113.50 ± 6.40 284.33 ± 19.74 224.00 ± 12.01 148.33 ± 2.04 4.54 ± 0.16 106.83 ± 1.38
20 121.00 ± 5.65 301.33 ± 34.20 260.33 ± 21.19 144.17 ± 2.56 4.60 ± 0.30 105.83 ± 1.22
40 148.33 ± 6.70 361.17 ± 64.02 327.00 ± 35.18 148.17 ± 1.97 4.48 ± 0.09 108.83 ± 1.35
80 188.33 ± 9.90* 853.17 ± 134.67* 841.83 ± 178.84* 147.50 ± 2.55 4.70 ± 0.29* 107.17 ± 2.04
(*) Indicates statistically significant difference (P < 0.05) from control by the Dunnett’s test
TABLE VI - Mean edema volume and percentage of inhibition at different time intervals in carrageenan-induced paw edema test
Treatment 
group
Mefenamic 
acid dosage 
(mg/kg)
Edema volume (mL) Inhibition (%)
1 h 2 h 3 h 4 h 5 h 6 h 1 h 2 h 3 h 4 h 5 h 6 h
Negative control 
(Vehicle only)
0
0.22 ± 
0.47
0.47 ± 
0.04
0.75 ± 
0.03
1.05 ± 
0.06
1.4 ± 0.04
1.57 ± 
0.09
N/A N/A N/A N/A N/A N/A
MFA-DDC 
based liposomes 
(PO)
0
0.26 ± 
0.059
0.49 ± 
0.07
0.70 ± 
0.05
0.89 ± 
0.04
1.13 ± 
0.06*
1.21 ± 
0.15*
-18.18 -4.26 6.67 15.24 19.29 22.93
20
0.22 ± 
0.029
0.45 ± 
0.07
0.68 ± 
0.04
0.78 ± 
0.02*
1.1 ± 
0.05*
1.31 ± 
0.20*
0.00 4.26 9.33 25.71 21.43 16.56
40
0.23 ± 
0.042
0.31 ± 
0.03
0.38 ± 
0.03*
0.55 ± 
0.05*
0.84 ± 
0.11*
0.81 ± 
0.22*
-4.55 34.04 49.33 47.62 40.00 48.41
80
0.06 ± 
0.02
0.12 ± 
0.01*
0.15 ± 
0.02*
0.33 ± 
0.03*
0.36 ± 
0.04*
0.35 ± 
0.09*
72.73 74.47 80.00 68.57 74.29 77.71
MFA-DDC 
based liposomes 
(IP)
0
0.22 ± 
0.16
0.41 ± 
0.03
0.67 ± 
0.04
0.86 ± 
0.03*
1.08 ± 
0.04*
1.17 ± 
0.05*
0.00 12.77 10.67 18.10 22.86 25.48
20
0.07 ± 
0.02
0.05 ± 
0.03*
0.05 ± 
0.03*
0.08 ± 
0.02*
0.09 ± 
0.03*
0.00 ± 
0.05*
68.18 89.36 93.33 92.38 93.57 94.27
(*) Indicates statistically significant difference (P < 0.05) from control by the Dunnett’s test.
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CONCLUSION 
On the whole, the prepared MFA-DDC based 
liposomes demonstrate satisfactory stability and 
reproducibility with high encapsulation efficacy and a 
sustained drug release profile in slightly acidic media 
which may enhance the targeting of the inflamed 
tissues. In addition, MFA-DDC based liposomes caused 
significant inhibition of paw edema when administrated 
by oral and intraperitoneal routes of administration. 
The intraperitoneally administrated MFA-DDC based 
liposomes were more potent and effective in reducing paw 
edema in rats than the orally administrated liposomes, 
suggesting a higher drug bioavailability resulted from 
the intraperitoneal route of administration. Based 
on these findings, the bioequivalence studies are 
recommended to compare the oral bioavailability and 
the in vivo performance of these liposomes with those 
of commercially available products of MFA. The present 
study also suggests further work on other routes of 
administration (i.e. intravenous and intramuscular) to find 
out the most appropriate route for clinical applications.
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